greeksoup/ stock research
Stock research / United States / GSK / Filings

GSK plc SEC filings

In the twelve months since 29 September 2025 GSK plc filed 300 documents with the SEC of the kinds listed here: 296 reports on Form 6-K, most often 111 transaction in own shares; 77 director/PDMR shareholding; 12 total voting rights; 3 admission to trading; 3 holding(s) in company; 2 employee plan annual reports (11-K), 1 conflict minerals report (SD), 1 annual report (foreign filer) (20-F). The latest, filed 24 September 2026: 6-K, director/pdmr shareholding.

FiledFormWhat it was aboutPeriod or event dateFiling
24 September 20266-KDirector/PDMR shareholding24 September 2026EDGAR
22 September 20266-KDirector/PDMR shareholding22 September 2026EDGAR
15 September 20266-KGSK to acquire T CELL-engager for multiple myeloma15 September 2026EDGAR
15 September 20266-Kno title given to EDGAR; the filing is linked15 September 2026EDGAR
14 September 20266-KRIS-REZ positive PH 3 OS LUNG cancer DATA in china14 September 2026EDGAR
14 September 20266-KJideytro positive DATA for ROS1-positive nsclc14 September 2026EDGAR
11 September 20266-KDirector/PDMR shareholding11 September 2026EDGAR
10 September 20266-KDirector/PDMR shareholding10 September 2026EDGAR
10 September 20266-KJapan approval of shingrix in a prefilled syringe10 September 2026EDGAR
9 September 20266-KDirector/PDMR shareholding9 September 2026EDGAR
9 September 20266-KDirector/PDMR shareholding9 September 2026EDGAR
8 September 20266-Kno title given to EDGAR; the filing is linked8 September 2026EDGAR
1 September 20266-KTotal voting rights1 September 2026EDGAR
1 September 20266-KMRNA FLU vaccine candidate to advance to phase III1 September 2026EDGAR
26 August 20266-KDirector/PDMR shareholding26 August 2026EDGAR
24 August 20266-KDirector/PDMR shareholding24 August 2026EDGAR
24 August 20266-KFirst global approval for hibsago in japan24 August 2026EDGAR
24 August 20266-KUS FDA to review jemperli for rectal cancer24 August 2026EDGAR
18 August 20266-KDirector/PDMR shareholding18 August 2026EDGAR
13 August 20266-KDirector/PDMR shareholding13 August 2026EDGAR
11 August 20266-KDirector/PDMR shareholding11 August 2026EDGAR
3 August 20266-KTotal voting rights3 August 2026EDGAR
30 July 20266-KDirector/PDMR shareholding30 July 2026EDGAR
28 July 20266-KNew GSK flagship R&D centre in cambridge28 July 2026EDGAR
28 July 20266-KHansoh positive 2ND phase III results for RIZ-REZ28 July 2026EDGAR
28 July 20266-K2ND quarter results28 July 2026EDGAR
24 July 20266-KDirector/PDMR shareholding24 July 2026EDGAR
24 July 20266-KAdmission to trading24 July 2026EDGAR
22 July 20266-KJideytro approved in US for certain LUNG cancers22 July 2026EDGAR
20 July 20266-KBexsero 1-DOSE booster EMA FILE acceptance20 July 2026EDGAR
17 July 20266-KAudit tender conclusion17 July 2026EDGAR
17 July 20266-KCamlipixant phase III results update17 July 2026EDGAR
16 July 20266-KDirector/PDMR shareholding16 July 2026EDGAR
15 July 20266-KGSK completes acquisition of nuvalent, INC15 July 2026EDGAR
14 July 20266-KDirector/PDMR shareholding14 July 2026EDGAR
13 July 20266-KDirector/PDMR shareholding13 July 2026EDGAR
13 July 20266-KPositive jemperli DATA in DMMR/MSI-H rectal cancer13 July 2026EDGAR
10 July 20266-KHansoh positive phase III results for RIZ-REZ10 July 2026EDGAR
9 July 20266-KDirector/PDMR shareholding9 July 2026EDGAR
9 July 20266-KDirectorate change9 July 2026EDGAR
1 July 20266-KTotal voting rights1 July 2026EDGAR
29 June 20266-KTransaction in own shares29 June 2026EDGAR
29 June 20266-KHolding(s) in company29 June 2026EDGAR
26 June 20266-KHolding(s) in company26 June 2026EDGAR
24 June 20266-KDirector/PDMR shareholding24 June 2026EDGAR
24 June 20266-KGSK announces tender offer to acquire nuvalent24 June 2026EDGAR
23 June 20266-KDirector/PDMR shareholding23 June 2026EDGAR
22 June 20266-KTransaction in own shares22 June 2026EDGAR
17 June 20266-KCUTI ORAL antibiotic tebipenem approved by US FDA17 June 2026EDGAR
17 June 202611-Kemployee plan annual report31 December 2025EDGAR
17 June 202611-Kemployee plan annual report31 December 2025EDGAR
15 June 20266-KTransaction in own shares15 June 2026EDGAR
12 June 20266-KMomelotinib orphan DRUG designations for vexas12 June 2026EDGAR
11 June 20266-KDirector/PDMR shareholding11 June 2026EDGAR
10 June 20266-KDirector/PDMR shareholding10 June 2026EDGAR
9 June 20266-KDR HAL barron - new directorship9 June 2026EDGAR
9 June 20266-KGSK enters agreement to acquire nuvalent, INC.9 June 2026EDGAR
8 June 20266-KTransaction in own shares8 June 2026EDGAR
1 June 20266-KTotal voting rights1 June 2026EDGAR
1 June 20266-KTransaction in own shares1 June 2026EDGAR
28 May 20266-KPositive phase 3 DATA for bepirovirsen28 May 2026EDGAR
27 May 20266-KDirector/PDMR shareholding27 May 2026EDGAR
26 May 2026SDconflict minerals reportEDGAR
26 May 20266-KAdmission to trading26 May 2026EDGAR
26 May 20266-KTransaction in own shares26 May 2026EDGAR
22 May 20266-KQ2 2026 results date confirmed - 28 JULY 202622 May 2026EDGAR
20 May 20266-KDirector/PDMR shareholding20 May 2026EDGAR
20 May 20266-KDirector/PDMR shareholding20 May 2026EDGAR
19 May 20266-KDirector/PDMR shareholding19 May 2026EDGAR
18 May 20266-KTransaction in own shares18 May 2026EDGAR
18 May 20266-KJapan MHLW approves arexvy for adults 18-49 AIR18 May 2026EDGAR
14 May 20266-KDirector/PDMR shareholding14 May 2026EDGAR
11 May 20266-KDirector/PDMR shareholding11 May 2026EDGAR
11 May 20266-KCollaboration with CTTQ for bepirovirsen11 May 2026EDGAR
11 May 20266-KGSK - final tranche of share buyback programme11 May 2026EDGAR
6 May 20266-KResult of AGM6 May 2026EDGAR
5 May 20266-KDirector/PDMR shareholding5 May 2026EDGAR
1 May 20266-KTotal voting rights1 May 2026EDGAR
1 May 20266-KHolding(s) in company1 May 2026EDGAR
29 April 20266-KDirector/PDMR shareholding29 April 2026EDGAR
29 April 20266-K1ST quarter results29 April 2026EDGAR
28 April 20266-KDirector/PDMR shareholding28 April 2026EDGAR
28 April 20266-KBepirovirsen priority review US filing acceptance28 April 2026EDGAR
27 April 20266-KEfimosfermin granted US/EU regulatory designations27 April 2026EDGAR
27 April 20266-KTesaro update on anaptysbio INC. litigation27 April 2026EDGAR
24 April 20266-KDirector/PDMR shareholding24 April 2026EDGAR
23 April 20266-KTransaction in own shares23 April 2026EDGAR
22 April 20266-KTransaction in own shares22 April 2026EDGAR
21 April 20266-KTransaction in own shares21 April 2026EDGAR
20 April 20266-KDirector/PDMR shareholding20 April 2026EDGAR
20 April 20266-KBlenrep approved in china for 2L+ multiple myeloma20 April 2026EDGAR
20 April 20266-KTransaction in own shares20 April 2026EDGAR
17 April 20266-KTransaction in own shares17 April 2026EDGAR
16 April 20266-KDirector/PDMR shareholding16 April 2026EDGAR
16 April 20266-KTransaction in own shares16 April 2026EDGAR
15 April 20266-KGSK completes acquisition of 35pharma INC.15 April 2026EDGAR
15 April 20266-KTransaction in own shares15 April 2026EDGAR
14 April 20266-KDirector/PDMR shareholding14 April 2026EDGAR
14 April 20266-KTransaction in own shares14 April 2026EDGAR
13 April 20266-KDirector/PDMR shareholding13 April 2026EDGAR
13 April 20266-KGSK presents positive DATA for behold 1 B7 H4 ADC13 April 2026EDGAR
13 April 20266-KTransaction in own shares13 April 2026EDGAR
10 April 20266-KDirector/PDMR shareholding10 April 2026EDGAR
10 April 20266-KTransaction in own shares10 April 2026EDGAR
9 April 20266-KDirector/PDMR shareholding9 April 2026EDGAR
9 April 20266-KTransaction in own shares9 April 2026EDGAR
8 April 20266-KExdensur approved for crswnp in china8 April 2026EDGAR
8 April 20266-KTransaction in own shares8 April 2026EDGAR
7 April 20266-KTransaction in own shares7 April 2026EDGAR
2 April 20266-KTransaction in own shares2 April 2026EDGAR
1 April 20266-KDirector/PDMR shareholding1 April 2026EDGAR
1 April 20266-KTotal voting rights1 April 2026EDGAR
1 April 20266-KTransaction in own shares1 April 2026EDGAR
1 April 20266-KVIIV completes changes to minority shareholding1 April 2026EDGAR
31 March 20266-KTransaction in own shares31 March 2026EDGAR
30 March 20266-KBepirovirsen accepted for review in china30 March 2026EDGAR
30 March 20266-KExdensur approved for severe asthma in china30 March 2026EDGAR
30 March 20266-KTransaction in own shares30 March 2026EDGAR
27 March 20266-KTransaction in own shares27 March 2026EDGAR
27 March 20266-KBepirovirsen accepted for review by the EMA27 March 2026EDGAR
26 March 20266-KTransaction in own shares26 March 2026EDGAR
25 March 20266-KDirector/PDMR shareholding25 March 2026EDGAR
25 March 20266-KNotice of AGM25 March 2026EDGAR
25 March 20266-KTransaction in own shares25 March 2026EDGAR
24 March 20266-KTransaction in own shares24 March 2026EDGAR
23 March 20266-KDirector/PDMR shareholding23 March 2026EDGAR
23 March 20266-KAdmission to trading23 March 2026EDGAR
23 March 20266-KGSK LUNG cancer ADC GETS japan orphan DRUG status23 March 2026EDGAR
23 March 20266-KTransaction in own shares23 March 2026EDGAR
20 March 20266-KTransaction in own shares20 March 2026EDGAR
19 March 20266-KLynavoy (linerixibat) approved by US FDA19 March 2026EDGAR
19 March 20266-KTransaction in own shares19 March 2026EDGAR
18 March 20266-KDirector/PDMR shareholding18 March 2026EDGAR
18 March 20266-KTransaction in own shares18 March 2026EDGAR
17 March 20266-KDirector/PDMR shareholding17 March 2026EDGAR
17 March 20266-KTransaction in own shares17 March 2026EDGAR
16 March 20266-KTransaction in own shares16 March 2026EDGAR
13 March 20266-KUS FDA approves arexvy for adults 18-49 AIR13 March 2026EDGAR
13 March 20266-KTransaction in own shares13 March 2026EDGAR
12 March 20266-KDirector/PDMR shareholding12 March 2026EDGAR
12 March 20266-KTransaction in own shares12 March 2026EDGAR
11 March 20266-KTransaction in own shares11 March 2026EDGAR
10 March 20266-KTransaction in own shares10 March 2026EDGAR
9 March 20266-KBoard committee change9 March 2026EDGAR
9 March 20266-KGSK and alfasigma agree global linerixibat rights9 March 2026EDGAR
9 March 20266-KTransaction in own shares9 March 2026EDGAR
6 March 20266-KFiling of GSK PLC 2025 annual report on form 20-f6 March 2026EDGAR
6 March 20266-KTransaction in own shares6 March 2026EDGAR
6 March 202620-Fannual report (foreign filer)31 December 2025EDGAR
5 March 20266-KGSK publishes annual report 20255 March 2026EDGAR
5 March 20266-KTransaction in own shares5 March 2026EDGAR
4 March 20266-KDirector/PDMR shareholding4 March 2026EDGAR
4 March 20266-KTransaction in own shares4 March 2026EDGAR
3 March 20266-KGSK completes acquisition of RAPT therapeutics3 March 2026EDGAR
3 March 20266-KTransaction in own shares3 March 2026EDGAR
2 March 20266-KTransaction in own shares2 March 2026EDGAR
2 March 20266-KTotal voting rights2 March 2026EDGAR
27 February 20266-KDirector/PDMR shareholding27 February 2026EDGAR
27 February 20266-KTransaction in own shares27 February 2026EDGAR
26 February 20266-KLinerixibat accepted for priority review in china26 February 2026EDGAR
26 February 20266-KBepirovirsen accepted for japan regulatory review26 February 2026EDGAR
26 February 20266-KTransaction in own shares26 February 2026EDGAR
25 February 20266-KDirector/PDMR shareholding25 February 2026EDGAR
25 February 20266-KDirector/PDMR shareholding25 February 2026EDGAR
25 February 20266-KGSK enters agreement to acquire 35pharma25 February 2026EDGAR
25 February 20266-KTransaction in own shares25 February 2026EDGAR
24 February 20266-KDirector/PDMR shareholding24 February 2026EDGAR
24 February 20266-KTransaction in own shares24 February 2026EDGAR
23 February 20266-KTransaction in own shares23 February 2026EDGAR
20 February 20266-KDirector/PDMR shareholding20 February 2026EDGAR
20 February 20266-KTransaction in own shares20 February 2026EDGAR
19 February 20266-KDirector/PDMR shareholding19 February 2026EDGAR
19 February 20266-KTransaction in own shares19 February 2026EDGAR
18 February 20266-KTransaction in own shares18 February 2026EDGAR
17 February 20266-KDirector/PDMR shareholding17 February 2026EDGAR
17 February 20266-KDirector/PDMR shareholding17 February 2026EDGAR
17 February 20266-KGSK - fourth tranche of share buyback programme17 February 2026EDGAR
17 February 20266-KExdensur approved by the european commission17 February 2026EDGAR
17 February 20266-KDirector/PDMR shareholding17 February 2026EDGAR
17 February 20266-KDirector/PDMR shareholding17 February 2026EDGAR
17 February 20266-KDirector/PDMR shareholding17 February 2026EDGAR
11 February 20266-KDirector/PDMR shareholding11 February 2026EDGAR
11 February 20266-KDirector/PDMR shareholding11 February 2026EDGAR
11 February 20266-KDirector/PDMR shareholding11 February 2026EDGAR
11 February 20266-KDirector/PDMR shareholding11 February 2026EDGAR
10 February 20266-KChina CDE accepts arexvy adults 60+ application10 February 2026EDGAR
9 February 20266-KDirector/PDMR shareholding9 February 2026EDGAR
6 February 20266-KDirector/PDMR shareholding6 February 2026EDGAR
6 February 20266-KNucala COPD approved by the european commission6 February 2026EDGAR
5 February 20266-KDirector/PDMR shareholding5 February 2026EDGAR
4 February 20266-KFinal results4 February 2026EDGAR
2 February 20266-KTotal voting rights2 February 2026EDGAR
26 January 20266-KEuropean commission approves arexvy for adults 18+26 January 2026EDGAR
20 January 20266-KGSK to acquire RAPT therapeutics20 January 2026EDGAR
20 January 20266-KAgreement on changes to VIIV minority shareholding20 January 2026EDGAR
16 January 20266-KDirector/PDMR shareholding16 January 2026EDGAR
15 January 20266-KDirector/PDMR shareholding15 January 2026EDGAR
13 January 20266-KDirector/PDMR shareholding13 January 2026EDGAR
7 January 20266-KEC approval of shingrix PFS7 January 2026EDGAR
7 January 20266-KPositive phase 3 DATA for GSK's bepirovirsen7 January 2026EDGAR

A foreign company listed in the US files a Form 6-K for what it publishes at home: results, share buybacks, directors' dealings, bond issues and notices. The 6-K carries no item numbers, so each is listed under the title the company gave EDGAR, where it gave one; the rest are linked to the filing itself. The annual report is the 20-F (or the 40-F for a Canadian filer). Form 144, 13F and Schedule 13D and 13G have their own pages; a foreign filer files no Form 4.

Source

The company's filing index on EDGAR, read from the SEC's submissions feed.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install